<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-053457</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Acute renal failure and proximal renal tubular dysfunction in a patient with acquired immunodeficiency syndrome treated with tenofovir</dc:title>
<dc:description xml:lang="en">Tenofovir, a new nucleotide reverse transcriptase inhibitor that has good antiviral activity    against drug-resistant strains of HIV, is structurally similar to cidofovir and adefovir and seems    to be less nephrotoxic. Nephrotoxicity of cidofovir and adefovir is well established and they    have been associated with increase for acute renal insufficiency due to tubular toxicity, possibly induced via mitochondrial deplection. Tenofovir has little mithocondrial toxicity in in vitro    assays and early clinical studies. However some cases of renal tubular dysfuntion and renal failure    related to tenofovir treatment have been published recently. Increased plasma concentrations    of didanosine were observed after the adition of tenofovir and protease inhibitors can interact    with the renal transport of organic anions leading to proximal tubular intracellular    accumulation of tenofovir, yield Fanconi syndrome-type tubulopathy. We present a case in wich    acute renal failure and proximal tubular dysfunction developed after therapy with tenofovir in    a patiente with HIV who had suffered from complications of didanosine treatment. Although    nephrotoxicity certainly occurs much less frequently with tenofovir that it does with other nuclotide    analogues, use of tenofovir by patients with underlying renal disfuntion, for longer durations    and/or associated with didanosine or lopinavir-ritonavir, might be associated with renal    toxicity. Patients receiving tenofovir must be monitored for sings of tubulopathy with simple    tests such us glycosuria, phosphaturia, proteinuria, phosphoremia and renal function, as well    as assessment for signs of mithocondrial toxicity when a nucleoside analogue is being administered,    and therapy should be stopped to avoid the risk of definitive renal failu</dc:description>
<dc:creator>Saus, C</dc:creator>
<dc:creator>Morey, A</dc:creator>
<dc:creator>Uriol, M</dc:creator>
<dc:creator>Prada, FJ de la</dc:creator>
<dc:creator>Prados, AM</dc:creator>
<dc:creator>Tugores, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Tenofovir es un nuevo inhibidor de la transcriptasa inversa con buena actividad frente a    cepas resistentes del virus de inmunodeficiencia humana (HIV), de estructura similar a adefovir    y cidofovir. Con éstos se ha descrito la aparición de un defecto en el transporte de    sustancias en el túbulo proximal. Los estudios in vitro y las primeras referencias clínicas    sobre tenofovir indicaban que presentaba poca toxicidad a nivel renal, y que su toxicidad    a nivel mitocondrial era escasa. No obstante se han descrito recientemente casos de disfunción    tubular proximal e insuficiencia renal relacionados con el uso de este fármaco. Además    tenofovir puede aumentar las concentraciones plasmáticas de didanosina, aumentando    la toxicidad mitocondrial de ésta, y los inhibidores de la proteasa pueden provocar una    acumulación de tenofovir en las células tubulares renales, pudiendo desarrollarse una tubulopatía    proximal. Presentamos una paciente HIV positiva que había presentado complicaciones    con el tratamiento con didanosina, que desarrolla un cuadro de insuficiencia renal    aguda y tubulopatía proximal (glucosuria normoglucémica, acidosis metabólica hiperclorémica)    tras el tratamiento con tenofovir. Aunque la nefrotoxicidad de este fármaco parece    ser menos frecuente que con otros análogos de nucleósidos, la utilización de tenofovir en    pacientes con disfunción renal subyacente, durante largos períodos de tiempo, o asociados    a didanosina y/o inhibidores de la proteasa, podría asociarse a ésta toxicidad. Si se utiliza    tenofovir en estos pacientes deben monitorizarse la aparición de signos de tubulopatía, además    de vigilar la función renal y la aparición de signos de toxicidad mitocondrial, suspendiendo    su utilización para evitar la progresión a insuficiencia renal avanzada</dc:description>
<dc:source>Nefrologia;26(5): 626-630, sept.-oct. 2006. ilus</dc:source>
<dc:identifier>ibc-053457</dc:identifier>
<dc:title xml:lang="es">Insuficiencia renal aguda y disfunción tubular proximal en paciente diagnosticado de infección VIH tratado con tenofovir</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d29364^s22057</dc:subject>
<dc:subject>^d5302^s22036</dc:subject>
<dc:subject>^d32626^s22020</dc:subject>
<dc:subject>^d233^s22003</dc:subject>
<dc:subject>^d10951^s22020</dc:subject>
<dc:subject>^d233^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33075^s22020</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d53982^s22036</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>200610</dc:date>
</metadata>
</record>
</ibecs-document>
